 | • レポートコード：MRC2Q12-17337 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療機器＆消耗品 |
| Single User | ￥710,500 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,421,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、播種性血管内凝固症候群診断のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 播種性血管内凝固症候群診断のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 播種性血管内凝固症候群診断の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 播種性血管内凝固症候群診断のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの播種性血管内凝固症候群診断の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の播種性血管内凝固症候群診断の売上および2028年までの予測に焦点を当てています。 播種性血管内凝固症候群診断のグローバル主要企業には、Abbott、AdvaCare Pharma、Axis-Shield Diagnostics、QuidelOrtho、CTK Biotech、AccuBioTech Co、Getein Biotech、PHC Holdings Corporation、Siemens Healthineers、Eurolyser Diagnostica GmbHなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 播種性血管内凝固症候群診断市場は、タイプとアプリケーションによって区分されます。世界の播種性血管内凝固症候群診断市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 血液塗抹検査式全血球計算、部分トロンボプラスチン時間（PTT）、プロトロンビン時間（PT）、フィブリノーゲン血液検査、D-ダイマー検査、その他 【アプリケーション別セグメント】 病院、外来センター、診断＆研究実験室、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 播種性血管内凝固症候群診断製品概要 - タイプ別市場（血液塗抹検査式全血球計算、部分トロンボプラスチン時間（PTT）、プロトロンビン時間（PT）、フィブリノーゲン血液検査、D-ダイマー検査、その他） - アプリケーション別市場（病院、外来センター、診断＆研究実験室、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の播種性血管内凝固症候群診断販売量予測2017-2028 - 世界の播種性血管内凝固症候群診断売上予測2017-2028 - 播種性血管内凝固症候群診断の地域別販売量 - 播種性血管内凝固症候群診断の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別播種性血管内凝固症候群診断販売量 - 主要メーカー別播種性血管内凝固症候群診断売上 - 主要メーカー別播種性血管内凝固症候群診断価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（血液塗抹検査式全血球計算、部分トロンボプラスチン時間（PTT）、プロトロンビン時間（PT）、フィブリノーゲン血液検査、D-ダイマー検査、その他） - 播種性血管内凝固症候群診断のタイプ別販売量 - 播種性血管内凝固症候群診断のタイプ別売上 - 播種性血管内凝固症候群診断のタイプ別価格 ・アプリケーション別市場規模（病院、外来センター、診断＆研究実験室、その他） - 播種性血管内凝固症候群診断のアプリケーション別販売量 - 播種性血管内凝固症候群診断のアプリケーション別売上 - 播種性血管内凝固症候群診断のアプリケーション別価格 ・北米市場 - 北米の播種性血管内凝固症候群診断市場規模（タイプ別、アプリケーション別） - 主要国別の播種性血管内凝固症候群診断市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの播種性血管内凝固症候群診断市場規模（タイプ別、アプリケーション別） - 主要国別の播種性血管内凝固症候群診断市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の播種性血管内凝固症候群診断市場規模（タイプ別、アプリケーション別） - 主要国別の播種性血管内凝固症候群診断市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の播種性血管内凝固症候群診断市場規模（タイプ別、アプリケーション別） - 主要国別の播種性血管内凝固症候群診断市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの播種性血管内凝固症候群診断市場規模（タイプ別、アプリケーション別） - 主要国別の播種性血管内凝固症候群診断市場規模（トルコ、サウジアラビア） ・企業情報 Abbott、AdvaCare Pharma、Axis-Shield Diagnostics、QuidelOrtho、CTK Biotech、AccuBioTech Co、Getein Biotech、PHC Holdings Corporation、Siemens Healthineers、Eurolyser Diagnostica GmbH ・産業チェーン及び販売チャネル分析 - 播種性血管内凝固症候群診断の産業チェーン分析 - 播種性血管内凝固症候群診断の原材料 - 播種性血管内凝固症候群診断の生産プロセス - 播種性血管内凝固症候群診断の販売及びマーケティング - 播種性血管内凝固症候群診断の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 播種性血管内凝固症候群診断の産業動向 - 播種性血管内凝固症候群診断のマーケットドライバー - 播種性血管内凝固症候群診断の課題 - 播種性血管内凝固症候群診断の阻害要因 ・主な調査結果 |
Disseminated intravascular coagulation (DIC) is a rare but serious condition that causes abnormal blood clotting throughout the body’s blood vessels. You may develop DIC if you have an infection or injury that affects the body’s normal blood clotting process.DIC is an acquired clinic biological syndrome characterized by widespread coagulation activation, which results in fibrin deposition in the vasculature, organ dysfunction, clotting factor and platelet consumption, and life-threatening hemorrhage. Several underlying disorders can cause disseminated intravascular coagulation (sepsis, cancer, trauma, and pregnancy complicated with eclampsia or other calamities). The cornerstone therapeutic approaches are treating the underlying disease and eliminating the trigger mechanism. DIC-specific therapeutic strategies aim to reduce blood coagulation activation and bleeding risk. Few clinical trials use DIC as an entry criterion.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Disseminated Intravascular Coagulation Diagnosis estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Disseminated Intravascular Coagulation Diagnosis is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Disseminated Intravascular Coagulation Diagnosis is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Disseminated Intravascular Coagulation Diagnosis is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Disseminated Intravascular Coagulation Diagnosis include Abbott, AdvaCare Pharma, Axis-Shield Diagnostics, QuidelOrtho, CTK Biotech, AccuBioTech Co, Getein Biotech, PHC Holdings Corporation and Siemens Healthineers, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Disseminated Intravascular Coagulation Diagnosis companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Disseminated Intravascular Coagulation Diagnosis market. Further, it explains the major drivers and regional dynamics of the global Disseminated Intravascular Coagulation Diagnosis market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Abbott
AdvaCare Pharma
Axis-Shield Diagnostics
QuidelOrtho
CTK Biotech
AccuBioTech Co
Getein Biotech
PHC Holdings Corporation
Siemens Healthineers
Eurolyser Diagnostica GmbH
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Disseminated Intravascular Coagulation Diagnosis Segment by Type
Complete Blood Count with Blood Smear Exam
Partial Thromboplastin Time (PTT)
Prothrombin Time (PT)
Fibrinogen Blood Test
D-dimer Test
Others
Disseminated Intravascular Coagulation Diagnosis Segment by Application
Hospital
Outpatient Center
Diagnostic and Research Laboratories
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Disseminated Intravascular Coagulation Diagnosis market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Disseminated Intravascular Coagulation Diagnosis market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Disseminated Intravascular Coagulation Diagnosis, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Disseminated Intravascular Coagulation Diagnosis, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Disseminated Intravascular Coagulation Diagnosis revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Disseminated Intravascular Coagulation Diagnosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Disseminated Intravascular Coagulation Diagnosis revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Abbott, AdvaCare Pharma, Axis-Shield Diagnostics, QuidelOrtho, CTK Biotech, AccuBioTech Co, Getein Biotech, PHC Holdings Corporation and Siemens Healthineers, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Disseminated Intravascular Coagulation Diagnosis in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Disseminated Intravascular Coagulation Diagnosis companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Disseminated Intravascular Coagulation Diagnosis revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Disseminated Intravascular Coagulation Diagnosis Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Complete Blood Count with Blood Smear Exam
1.2.3 Partial Thromboplastin Time (PTT)
1.2.4 Prothrombin Time (PT)
1.2.5 Fibrinogen Blood Test
1.2.6 D-dimer Test
1.2.7 Others
1.3 Market by Application
1.3.1 Global Disseminated Intravascular Coagulation Diagnosis Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Outpatient Center
1.3.4 Diagnostic and Research Laboratories
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Disseminated Intravascular Coagulation Diagnosis Market Perspective (2017-2028)
2.2 Disseminated Intravascular Coagulation Diagnosis Growth Trends by Region
2.2.1 Disseminated Intravascular Coagulation Diagnosis Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Disseminated Intravascular Coagulation Diagnosis Historic Market Size by Region (2017-2022)
2.2.3 Disseminated Intravascular Coagulation Diagnosis Forecasted Market Size by Region (2023-2028)
2.3 Disseminated Intravascular Coagulation Diagnosis Market Dynamics
2.3.1 Disseminated Intravascular Coagulation Diagnosis Industry Trends
2.3.2 Disseminated Intravascular Coagulation Diagnosis Market Drivers
2.3.3 Disseminated Intravascular Coagulation Diagnosis Market Challenges
2.3.4 Disseminated Intravascular Coagulation Diagnosis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Disseminated Intravascular Coagulation Diagnosis Players by Revenue
3.1.1 Global Top Disseminated Intravascular Coagulation Diagnosis Players by Revenue (2017-2022)
3.1.2 Global Disseminated Intravascular Coagulation Diagnosis Revenue Market Share by Players (2017-2022)
3.2 Global Disseminated Intravascular Coagulation Diagnosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Disseminated Intravascular Coagulation Diagnosis Revenue
3.4 Global Disseminated Intravascular Coagulation Diagnosis Market Concentration Ratio
3.4.1 Global Disseminated Intravascular Coagulation Diagnosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Disseminated Intravascular Coagulation Diagnosis Revenue in 2021
3.5 Disseminated Intravascular Coagulation Diagnosis Key Players Head office and Area Served
3.6 Key Players Disseminated Intravascular Coagulation Diagnosis Product Solution and Service
3.7 Date of Enter into Disseminated Intravascular Coagulation Diagnosis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Disseminated Intravascular Coagulation Diagnosis Breakdown Data by Type
4.1 Global Disseminated Intravascular Coagulation Diagnosis Historic Market Size by Type (2017-2022)
4.2 Global Disseminated Intravascular Coagulation Diagnosis Forecasted Market Size by Type (2023-2028)
5 Disseminated Intravascular Coagulation Diagnosis Breakdown Data by Application
5.1 Global Disseminated Intravascular Coagulation Diagnosis Historic Market Size by Application (2017-2022)
5.2 Global Disseminated Intravascular Coagulation Diagnosis Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Disseminated Intravascular Coagulation Diagnosis Market Size (2017-2028)
6.2 North America Disseminated Intravascular Coagulation Diagnosis Market Size by Type
6.2.1 North America Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2017-2022)
6.2.2 North America Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2023-2028)
6.2.3 North America Disseminated Intravascular Coagulation Diagnosis Market Share by Type (2017-2028)
6.3 North America Disseminated Intravascular Coagulation Diagnosis Market Size by Application
6.3.1 North America Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2017-2022)
6.3.2 North America Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2023-2028)
6.3.3 North America Disseminated Intravascular Coagulation Diagnosis Market Share by Application (2017-2028)
6.4 North America Disseminated Intravascular Coagulation Diagnosis Market Size by Country
6.4.1 North America Disseminated Intravascular Coagulation Diagnosis Market Size by Country (2017-2022)
6.4.2 North America Disseminated Intravascular Coagulation Diagnosis Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Disseminated Intravascular Coagulation Diagnosis Market Size (2017-2028)
7.2 Europe Disseminated Intravascular Coagulation Diagnosis Market Size by Type
7.2.1 Europe Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2017-2022)
7.2.2 Europe Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2023-2028)
7.2.3 Europe Disseminated Intravascular Coagulation Diagnosis Market Share by Type (2017-2028)
7.3 Europe Disseminated Intravascular Coagulation Diagnosis Market Size by Application
7.3.1 Europe Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2017-2022)
7.3.2 Europe Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2023-2028)
7.3.3 Europe Disseminated Intravascular Coagulation Diagnosis Market Share by Application (2017-2028)
7.4 Europe Disseminated Intravascular Coagulation Diagnosis Market Size by Country
7.4.1 Europe Disseminated Intravascular Coagulation Diagnosis Market Size by Country (2017-2022)
7.4.2 Europe Disseminated Intravascular Coagulation Diagnosis Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size (2017-2028)
8.2 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size by Type
8.2.1 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Share by Type (2017-2028)
8.3 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size by Application
8.3.1 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Share by Application (2017-2028)
8.4 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size by Region
8.4.1 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Disseminated Intravascular Coagulation Diagnosis Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size (2017-2028)
9.2 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size by Type
9.2.1 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2017-2022)
9.2.2 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2023-2028)
9.2.3 Latin America Disseminated Intravascular Coagulation Diagnosis Market Share by Type (2017-2028)
9.3 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size by Application
9.3.1 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2017-2022)
9.3.2 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2023-2028)
9.3.3 Latin America Disseminated Intravascular Coagulation Diagnosis Market Share by Application (2017-2028)
9.4 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size by Country
9.4.1 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size by Country (2017-2022)
9.4.2 Latin America Disseminated Intravascular Coagulation Diagnosis Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size (2017-2028)
10.2 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size by Type
10.2.1 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Share by Type (2017-2028)
10.3 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size by Application
10.3.1 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Share by Application (2017-2028)
10.4 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size by Country
10.4.1 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Disseminated Intravascular Coagulation Diagnosis Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Disseminated Intravascular Coagulation Diagnosis Introduction
11.1.4 Abbott Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.1.5 Abbott Recent Developments
11.2 AdvaCare Pharma
11.2.1 AdvaCare Pharma Company Details
11.2.2 AdvaCare Pharma Business Overview
11.2.3 AdvaCare Pharma Disseminated Intravascular Coagulation Diagnosis Introduction
11.2.4 AdvaCare Pharma Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.2.5 AdvaCare Pharma Recent Developments
11.3 Axis-Shield Diagnostics
11.3.1 Axis-Shield Diagnostics Company Details
11.3.2 Axis-Shield Diagnostics Business Overview
11.3.3 Axis-Shield Diagnostics Disseminated Intravascular Coagulation Diagnosis Introduction
11.3.4 Axis-Shield Diagnostics Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.3.5 Axis-Shield Diagnostics Recent Developments
11.4 QuidelOrtho
11.4.1 QuidelOrtho Company Details
11.4.2 QuidelOrtho Business Overview
11.4.3 QuidelOrtho Disseminated Intravascular Coagulation Diagnosis Introduction
11.4.4 QuidelOrtho Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.4.5 QuidelOrtho Recent Developments
11.5 CTK Biotech
11.5.1 CTK Biotech Company Details
11.5.2 CTK Biotech Business Overview
11.5.3 CTK Biotech Disseminated Intravascular Coagulation Diagnosis Introduction
11.5.4 CTK Biotech Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.5.5 CTK Biotech Recent Developments
11.6 AccuBioTech Co
11.6.1 AccuBioTech Co Company Details
11.6.2 AccuBioTech Co Business Overview
11.6.3 AccuBioTech Co Disseminated Intravascular Coagulation Diagnosis Introduction
11.6.4 AccuBioTech Co Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.6.5 AccuBioTech Co Recent Developments
11.7 Getein Biotech
11.7.1 Getein Biotech Company Details
11.7.2 Getein Biotech Business Overview
11.7.3 Getein Biotech Disseminated Intravascular Coagulation Diagnosis Introduction
11.7.4 Getein Biotech Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.7.5 Getein Biotech Recent Developments
11.8 PHC Holdings Corporation
11.8.1 PHC Holdings Corporation Company Details
11.8.2 PHC Holdings Corporation Business Overview
11.8.3 PHC Holdings Corporation Disseminated Intravascular Coagulation Diagnosis Introduction
11.8.4 PHC Holdings Corporation Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.8.5 PHC Holdings Corporation Recent Developments
11.9 Siemens Healthineers
11.9.1 Siemens Healthineers Company Details
11.9.2 Siemens Healthineers Business Overview
11.9.3 Siemens Healthineers Disseminated Intravascular Coagulation Diagnosis Introduction
11.9.4 Siemens Healthineers Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.9.5 Siemens Healthineers Recent Developments
11.10 Eurolyser Diagnostica GmbH
11.10.1 Eurolyser Diagnostica GmbH Company Details
11.10.2 Eurolyser Diagnostica GmbH Business Overview
11.10.3 Eurolyser Diagnostica GmbH Disseminated Intravascular Coagulation Diagnosis Introduction
11.10.4 Eurolyser Diagnostica GmbH Revenue in Disseminated Intravascular Coagulation Diagnosis Business (2017-2022)
11.10.5 Eurolyser Diagnostica GmbH Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
| 【播種性血管内凝固症候群診断について】 播種性血管内凝固症候群（DIC）は、病的な血液凝固が全身的に発生する状態を指します。この症候群は、一時的には血液が凝固しやすくなり、その後に出血傾向が現れるという、二重の病態を特徴としています。DICは、さまざまな基礎疾患に関連し、重篤な状態になることがあります。ここでは、DICの定義、特徴、種類、用途、関連技術について詳しく解説いたします。 まず、DICの定義について説明します。DICは、血管内での異常な凝固反応が引き起こされ、微小血管内に凝固塊が形成されることで、末梢組織への血流が改善されなくなり、組織の損傷が生じることによる疾患です。この状況は、出血傾向も引き起こすため、患者の症状は多様であり、臨床的には非常に難治性の状態となることが多いです。 DICの特徴として、まず凝固系の活性化が挙げられます。凝固因子が過剰に活性化されることで、血栓が形成され、その結果として微小循環障害を引き起こします。この状態が続くと、凝固因子が枯渇し、出血傾向が現れることになります。また、DICは急性と慢性に大別されます。急性DICは急速に進行し、感染症、外傷、重篤な病態（例：悪性腫瘍、産科的合併症など）に伴うことが多いのに対し、慢性DICは徐々に進行し、特に悪性腫瘍に伴うことが多いです。 DICの原因としては、主に以下のようなものがあります。感染症、特に細菌感染（例：敗血症など）は、DICの最も一般的な引き金となります。また、外傷、手術、出血、妊娠中の合併症（例：胎盤剥離、子癇前症など）、または悪性腫瘍の進行にも連動します。これらの病態では、組織からのトロンボプラスチンが放出され、凝固系が活性化されることによってDICが引き起こされます。 DICの病態生理学は非常に複雑で、血管内皮の損傷、炎症反応、凝固因子の異常活性化、抗凝固系の機能不全が絡み合っています。特に、IL-6やTNF-αなどの炎症性サイトカインがDICを悪化させる要因として重要視されています。これにより、血栓形成が促進され、同時に出血傾向が強まるという二重のメカニズムが働くこととなります。 DICの症状は多岐にわたります。主な症状としては、皮膚や粘膜からの出血、青あざ、点状出血（紫斑）、内臓出血などが見られます。また、微小循環障害により、臓器障害が生じることもあります。特に腎機能の障害、肝機能の低下、肺の障害などが著名で、重篤な場合には多臓器不全に至ることがあります。そのため、早期の診断と治療が極めて重要です。 DICの診断には、臨床症状の確認に加え、血液検査が行われます。凝固系の異常を示す検査としては、PT（プロトロンビン時間）、APTT（活性化部分トロンボプラスチン時間）、フィブリノゲン値、Dダイマー値などが用いられます。Dダイマーは、血栓が分解される際に生成される指標で、DIC患者ではその値が著しく上昇します。これらの検査結果を総合的に評価することで、DICの診断が行われます。 DICの治療方針は、基礎疾患の治療を中心に構築されます。例えば、感染症が原因であれば抗生物質の投与が必要です。出血傾向が強い場合、輸血療法や凝固因子の補充が行われます。また、抗凝固療法が適応されることもあります。これにはヘパリンの投与が含まれますが、出血リスクの管理が重要です。 DICの治療に関連する技術も進化しています。例えば、血漿交換や血液浄化療法が行われることもあれば、抗炎症薬の使用も検討されます。また、最近の研究では、DICの進行を防ぐための新たな分子標的療法への期待も高まっています。たとえば、トロンビンやフィブリンの生成を抑制する薬剤が開発されつつあります。 DICは、生命を脅かす重篤な状態であり、早期の診断と迅速な治療が求められます。基礎疾患の適切な管理と、症状に応じた適切な治療がDICの予後を左右します。医療者は、DICのリスク因子や早期兆候を認識し、患者を観察しながら適切な対応を行うことが重要です。この疾患に対する理解と研究は依然として進行中であり、新たな治療法やアプローチの開発が期待されています。DICについての知識を深めることは、医療従事者にとっても患者にとっても、その治療の質を向上させるために不可欠であると言えるでしょう。 |